Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

Raymond, 2002, Conventional osteosarcoma, 264 Stiller, 2006, Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project, Eur J Cancer, 42, 2124, 10.1016/j.ejca.2006.05.015 Mirabello, 2009, International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons, Int J Cancer, 125, 229, 10.1002/ijc.24320 Mirabello, 2009, Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program, Cancer, 115, 1531, 10.1002/cncr.24121 Campanacci, 1975, Osteosarcoma: A review of 345 cases, Ital J Orthop Traumatol, 1, 5 Uribe-Botero, 1977, Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54, Am J Clin Pathol, 67, 427, 10.1093/ajcp/67.5.427 Cohen, 1978, Osteosarcoma of the long bones. Clinical observations and experiences in the Netherlands, Eur J Cancer, 14, 995, 10.1016/0014-2964(78)90027-0 Mulder JD, Schütte HE, Kroon HM, Taconis WK. Radiologic atlas of bone tumors. 2 ed. Amsterdam, Elsevier, 1993. Unni KK. Dahlin’s Bone Tumors General Aspects and Data on 11,087 Cases. 5th ed. Philadelphia, Lippincott-Raven Publishers, 1996. Bielack, 2002, Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1, 702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols, J Clin Oncol, 20, 776, 10.1200/JCO.20.3.776 Stiller, 2001, Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study, Eur J Cancer, 37, 760, 10.1016/S0959-8049(01)00004-1 Gatta, 2002, Childhood cancer survival in Europe and the United States, Cancer, 95, 1767, 10.1002/cncr.10833 Gatta, 2005, Childhood cancer survival trends in Europe: a EUROCARE Working Group study, J Clin Oncol, 23, 3742, 10.1200/JCO.2005.00.554 Magnani, 2006, Trends in survival after childhood cancer in Europe, 1978–1997: report from the Automated Childhood Cancer Information System project (ACCIS), Eur J Cancer, 42, 1981, 10.1016/j.ejca.2006.05.006 Stiller, 2006, Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994, Br J Cancer, 94, 22, 10.1038/sj.bjc.6602885 Gatta, 2009, Survival of European children and young adults with cancer diagnosed 1995–2002, Eur J Cancer, 45, 992, 10.1016/j.ejca.2008.11.042 Fiocco, 2009, A new serially correlated gamma-frailty process for longitudinal count data, Biostatistics, 10, 245, 10.1093/biostatistics/kxn031 Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 Fiocco, 2009, Meta-analysis of pairs of survival curves under heterogeneity: a Poisson correlated gamma-frailty approach, Stat Med, 28, 3782, 10.1002/sim.3752 Cortes, 1978, Amputation and adriamycin in primary osteosarcoma: a 5-year report, Cancer Treat Rep, 62, 271 Campanacci, 1981, The treatment of osteosarcoma of the extremities: twenty year’s experience at the Istituto Ortopedico Rizzoli, Cancer, 48, 1569, 10.1002/1097-0142(19811001)48:7<1569::AID-CNCR2820480717>3.0.CO;2-X Jaffe, 1983, Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy, J Clin Oncol, 1, 251, 10.1200/JCO.1983.1.4.251 Link, 1986, The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity, N Engl J Med, 314, 1600, 10.1056/NEJM198606193142502 Huth, 1989, Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases1, Arch Surg, 124, 122, 10.1001/archsurg.1989.01410010132026 Goorin, 1991, Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study1, J Clin Oncol, 9, 600, 10.1200/JCO.1991.9.4.600 Bacci, 2001, Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy9, Eur J Cancer, 37, 32, 10.1016/S0959-8049(00)00361-0 Lindbom, 1961, Osteosarcoma. A review of 96 cases, Acta Radiol, 56, 1, 10.3109/00016926109172565 ES, 1964, Osteosarcoma. A study of the value of preoperative megavoltage radiotherapy, Br J Surg, 51, 252, 10.1002/bjs.1800510405 Marcove, 1970, Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases, J Bone Joint Surg Am, 52, 411, 10.2106/00004623-197052030-00001 Gaffney, 2006, Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era, Hum Pathol, 37, 1009, 10.1016/j.humpath.2006.02.022 Poppe, 1968, Osteosarcoma, Acta Chir Scand, 134, 549 Price, 1973, Metastatic spread of osteosarcoma, Br J Cancer, 28, 515, 10.1038/bjc.1973.181 Bonadonna, 1970, Phase I and preliminary phase II evaluation of adriamycin (NSC 123127), Cancer Res, 30, 2572 Middleman, 1971, Clinical trials with adriamycin, Cancer, 28, 844, 10.1002/1097-0142(1971)28:4<844::AID-CNCR2820280407>3.0.CO;2-9 Wang, 1971, Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease, Cancer, 28, 837, 10.1002/1097-0142(1971)28:4<837::AID-CNCR2820280406>3.0.CO;2-4 Cores, 1972, Doxorubicin in disseminated osteosarcoma, JAMA, 221, 1132, 10.1001/jama.221.10.1132 Friedman, 1972, The therapy of osteogenic sarcoma: current status and thoughts for the future, J Surg Oncol, 4, 482, 10.1002/jso.2930040512 O’Bryan, 1973, Phase II evaluation of adriamycin in human neoplasia, Cancer, 32, 1, 10.1002/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X Tan, 1973, Adriamycin – an antitumor antibiotic in the treatment of neoplastic diseases, Cancer, 1, 9, 10.1002/1097-0142(197307)32:1<9::AID-CNCR2820320102>3.0.CO;2-6 Benjamin, 1974, Adriamycin chemotherapy–efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule, Cancer, 33, 19, 10.1002/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M Pratt, 1974, Doxorubicin in treatment of malignant solid tumors in children, Am J Dis Child, 127, 534 Ragab, 1975, Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study, Cancer, 36, 1567, 10.1002/1097-0142(197511)36:5<1567::AID-CNCR2820360505>3.0.CO;2-I van Dyk, 1976, Adriamycin in the treatment of cancer, S Afr Med J, 50, 61 Schoenfeld, 1982, A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma, Cancer, 50, 2757, 10.1002/1097-0142(19821215)50:12<2757::AID-CNCR2820501211>3.0.CO;2-J Niederle, 1983, Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas, Cancer Treat Rev, 10, 129, 10.1016/S0305-7372(83)80018-8 Antman, 1985, Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma, Cancer Treat Rep, 69, 499 Marti, 1985, High-dose ifosfamide in advanced osteosarcoma, Cancer Treat Rep, 69, 115 Magrath, 1986, A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people, Cancer Chemother Pharmacol, 18, S25, 10.1007/BF00647446 Antman, 1989, Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma, J Clin Oncol, 7, 126, 10.1200/JCO.1989.7.1.126 Pinkerton, 1989, A phase II study of ifosfamide in paediatric solid tumours, Cancer Chemother Pharmacol, 24, S13 Schwartzman, 1989, Phase II study of ifosfamide as a single drug for relapsed paediatric patients, Cancer Chemother Pharmacol, 24, S11 Chawla SP, Rosen G, Lowenbraun S, Morton D, Eilber F. Role of high dose ifosphamide (HDI) in recurent osteosarcoma. ASCO Annual Meeting Proceedings 1990;9:310. Benjamin, 1993, Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience, Cancer Chemother Pharmacol, 31, S174 Harris, 1995, Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study, Med Pediatr Oncol, 24, 87, 10.1002/mpo.2950240205 Gullu, 1996, High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas, Cancer Invest, 14, 239, 10.3109/07357909609012146 Picci P, Bacci G, Ferrari S, Comandone A, Tienghi A. Salvage treatment with high dose ifosfamide and surgery for osteosarcoma patients relapsed with lung metastases. Preliminary Results. ASCO Annual Meeting Proceedings 1996;14:459. Pratt, 1996, Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience, Med Pediatr Oncol, 27, 145, 10.1002/(SICI)1096-911X(199609)27:3<145::AID-MPO2>3.0.CO;2-E Berrak, 2005, High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity, Pediatr Blood Cancer, 44, 215, 10.1002/pbc.20228 Meazza, 2010, Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma, Pediatr Blood Cancer, 55, 617, 10.1002/pbc.22596 Jaffe, 1973, Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy, Cancer, 31, 1367, 10.1002/1097-0142(197306)31:6<1367::AID-CNCR2820310611>3.0.CO;2-6 Jaffe, 1974, Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors, Cancer Chemother Rep, 58, 275 Pratt, 1974, Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-“leucovorin rescue” for children with malignant tumors, Cancer Res, 34, 3326 Ambinder, 1979, High dose methotrexate followed by citrovorum factor reversal in patients with advanced cancer, Cancer, 43, 1177, 10.1002/1097-0142(197904)43:4<1177::AID-CNCR2820430403>3.0.CO;2-R Rosen G, Nirenberg A, Juergens H, Caparros B, Huvos AG. Response of primary osteogenic sarcoma to single agent therapy with high-dose methotrexate with citrovorum factor rescue. In: Current chemotherapy and infectious diseases. Proceedings of the 11th international congress of chemotherapy and the 19th interscience conference on antimicrobial agents and chemotherapy; 1979. p.1633-5. Frei, 1980, High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity, Am J Med, 68, 370, 10.1016/0002-9343(80)90105-9 Pratt, 1980, High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma, Cancer Treat Rep, 64, 11 Kimura, 1981, High-dose methotrexate for adult malignancies, Experimental and clinical results. Cancer Bulletin, 33, 67 Jaffe, 1984, Chemotherapy for primary osteosarcoma by intra-arterial infusion. Review of the literature and comparison with results achieved by the intravenous route, Cancer Bulletin, 36, 37 Jaffe, 1985, Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma, J Clin Oncol, 3, 1101, 10.1200/JCO.1985.3.8.1101 Wagener, 1986, Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer, Cancer Treat Rep, 70, 615 Nitschke, 1978, Cis-diamminedichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study, Med Pediatr Oncol, 4, 127, 10.1002/mpo.2950040208 Ochs, 1978, Cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma, Cancer Treat Rep, 62, 239 Baum, 1981, Phase II trail cisplatin in refractory childhood cancer: Children’s Cancer Study Group Report, Cancer Treat Rep, 65, 815 Mavligit, 1981, Intraarterial cis-platinum for patients with inoperable skeletal tumors, Cancer, 48, 1, 10.1002/1097-0142(19810701)48:1<1::AID-CNCR2820480102>3.0.CO;2-R Jaffe, 1983, Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies, Cancer, 51, 402, 10.1002/1097-0142(19830201)51:3<402::AID-CNCR2820510308>3.0.CO;2-P Gasparini, 1985, Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Cancer Treat Rep, 69, 211 Pratt, 1985, Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin-doxorubicin, Cancer, 56, 1930, 10.1002/1097-0142(19851015)56:8<1930::AID-CNCR2820560806>3.0.CO;2-U Abe, 2002, Preoperative cisplatin for initial treatment of limb osteosarcoma: its local effect and impact on prognosis, Cancer Chemother Pharmacol, 50, 320, 10.1007/s00280-002-0501-z Chard, 1979, Phase II study of VP-16–213 in childhood malignant disease: a Children’s Cancer Study Group Report, Cancer Treat Rep, 63, 1755 Nissen, 1980, Clinical trial of VP 16–213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B, Cancer, 45, 232, 10.1002/1097-0142(19800115)45:2<232::AID-CNCR2820450206>3.0.CO;2-F O’Dwyer, 1985, Etoposide (VP-16–213). Current status of an active anticancer drug, N Engl J Med, 312, 692, 10.1056/NEJM198503143121106 Kung, 1988, Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group, Invest New Drugs, 6, 31, 10.1007/BF00170776 Rosen, 1976, Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma, Cancer, 37, 1, 10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3 Rosen, 1979, Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery, Cancer, 43, 2163, 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S Rosen, 1981, Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7), Natl Cancer Inst Monogr, 56, 213 Rosen, 1982, Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy, Cancer, 49, 1221, 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E Rosen, 1983, Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy, J Cancer Res Clin Oncol, 106, 55, 10.1007/BF00625054 Meyers, 1992, Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience, J Clin Oncol, 10, 5, 10.1200/JCO.1992.10.1.5 Meyers, 1998, Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol, J Clin Oncol, 16, 2452, 10.1200/JCO.1998.16.7.2452 Hudson, 1990, Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience, J Clin Oncol, 8, 1988, 10.1200/JCO.1990.8.12.1988 Jaffe, 2002, Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?, Cancer, 95, 2202, 10.1002/cncr.10944 Jaffe, 1991, Intraarterial cisplatin in the management of stage IIB osteosarcoma in the pediatric and adolescent age group, Clin Orthop Relat Res, 270, 15, 10.1097/00003086-199109000-00004 Miser, 1993, Osteosarcoma in adolescents and young adults: new developments and controversies. The Children’s Cancer Group (CCG) studies, Cancer Treat Res, 62, 287, 10.1007/978-1-4615-3518-8_34 Provisor, 1997, Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group, J Clin Oncol, 15, 76, 10.1200/JCO.1997.15.1.76 Goorin, 2003, Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651, J Clin Oncol, 21, 1574, 10.1200/JCO.2003.08.165 Zalupski, 2004, Adjuvant therapy of osteosarcoma–A Phase II trial: Southwest Oncology Group study 9139, Cancer, 100, 818, 10.1002/cncr.20021 Meyers, 2005, Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate, J Clin Oncol, 23, 2004, 10.1200/JCO.2005.06.031 Meyers, 2008, Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the Children’s Oncology Group, J Clin Oncol, 26, 633, 10.1200/JCO.2008.14.0095 Hunsberger, 2008, Complexities in interpretation of osteosarcoma clinical trial results, J Clin Oncol, 26, 3103, 10.1200/JCO.2008.17.3484 Petrilli, 2006, Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival, J Clin Oncol, 24, 1161, 10.1200/JCO.2005.03.5352 Winkler, 1983, Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study, J Cancer Res Clin Oncol, 106, 1, 10.1007/BF00625042 Winkler, 1984, Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study, J Clin Oncol, 2, 617, 10.1200/JCO.1984.2.6.617 Winkler, 1988, Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response, J Clin Oncol, 6, 329, 10.1200/JCO.1988.6.2.329 Winkler, 1993, Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS), Cancer Treat Res, 62, 269, 10.1007/978-1-4615-3518-8_32 Fuchs, 1998, Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs, Ann Oncol, 9, 893, 10.1023/A:1008391103132 Winkler, 1990, Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86), Cancer, 66, 1703, 10.1002/1097-0142(19901015)66:8<1703::AID-CNCR2820660809>3.0.CO;2-V Bacci, 1990, Cancer, 65, 2539, 10.1002/1097-0142(19900601)65:11<2539::AID-CNCR2820651125>3.0.CO;2-M Ferrari, 1997, Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy, Ann Oncol, 8, 765, 10.1023/A:1008221713505 Bacci, 1991, Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities, Clin Orthop Relat Res, 270, 87, 10.1097/00003086-199109000-00014 Bacci, 1993, Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy, Cancer, 71, 1224, 10.1002/1097-0142(19930215)71:4<1224::AID-CNCR2820710409>3.0.CO;2-M Ferrari, 1999, Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response, Tumori, 85, 458, 10.1177/030089169908500607 Bacci, 2001, Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol, Eur J Cancer, 37, 2030, 10.1016/S0959-8049(01)00229-5 Bacci, 2002, High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study, J Chemother, 14, 198, 10.1179/joc.2002.14.2.198 Ferrari, 2005, Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups, J Clin Oncol, 23, 8845, 10.1200/JCO.2004.00.5785 Bacci, 2001, A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity, Eur J Surg Oncol, 27, 98, 10.1053/ejso.2000.1056 Saeter, 1991, Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study, J Clin Oncol, 9, 1766, 10.1200/JCO.1991.9.10.1766 Saeter, 1999, Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience, Acta Orthop Scand Suppl, 285, 74, 10.1080/17453674.1999.11744828 Smeland, 2003, Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders, Eur J Cancer, 39, 488, 10.1016/S0959-8049(02)00747-5 Bramwell, 1992, A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup, J Clin Oncol, 10, 1579, 10.1200/JCO.1992.10.10.1579 Souhami, 1997, Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup, Lancet, 350, 911, 10.1016/S0140-6736(97)02307-6 Lewis, 2007, Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup, J Natl Cancer Inst, 99, 112, 10.1093/jnci/djk015 Kalifa, 1993, Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute, Cancer Treat Res, 62, 347, 10.1007/978-1-4615-3518-8_42 Philip, 1999, Ann Oncol, 10, 1065, 10.1023/A:1008395126800 Le Deley, 2007, SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients, Eur J Cancer, 43, 752, 10.1016/j.ejca.2006.10.023 Tunn, 2007, Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients, Onkologie, 30, 228, 10.1159/000100776 Bacci, 1993, Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies, J Chemother, 5, 237, 10.1080/1120009X.1993.11739239 Kawai, 1996, The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma, Arch Orthop Trauma Surg, 115, 68, 10.1007/BF00573443 Leung, 1997, Prognostic significance of chemotherapy dosage characteristics in children with osteogenic sarcoma, Med Pediatr Oncol, 28, 179, 10.1002/(SICI)1096-911X(199703)28:3<179::AID-MPO4>3.0.CO;2-G Lewis, 2000, Received dose and dose intensity of chemotherapy and outcome in non-metastatic extremity osteosarcoma, J Clin Oncol, 18, 4028, 10.1200/JCO.2000.18.24.4028 Bacci, 2000, Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report, J Clin Oncol, 18, 4016, 10.1200/JCO.2000.18.24.4016 Jaffe, 1993, Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)–advantages, disadvantages, and controversial issues, Cancer Treat Res, 62, 75, 10.1007/978-1-4615-3518-8_11 Cullen, 2005, The value of serial arteriography in osteosarcoma: delivery of chemotherapy, determination of therapy duration, and prediction of necrosis, J Vasc Interv Radiol, 16, 1107, 10.1097/01.RVI.0000167856.31329.F8 Hugate, 2008, Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults, Clin Orthop Relat Res, 466, 1292, 10.1007/s11999-008-0252-1 Bielack, 1993, Intraarterial chemotherapy for osteosarcoma: does the result really justify the effort?, Cancer Treat Res, 62, 85, 10.1007/978-1-4615-3518-8_12 Bielack, 1999, Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients, Klin Padiatr, 211, 260, 10.1055/s-2007-1019701 Eselgrim, 2006, Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials, Pediatr Blood Cancer, 47, 42, 10.1002/pbc.20608 Bacci, 2006, Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution, Cancer, 106, 1154, 10.1002/cncr.21724 Nardin, 2006, Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma, Curr Cancer Drug Targets, 6, 123, 10.2174/156800906776056473 Buddingh, 2011, Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents, Clin Cancer Res, 17, 2110, 10.1158/1078-0432.CCR-10-2047 Muller, 2005, Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series, Acta Oncol, 44, 475, 10.1080/02841860510029978 Whelan, 2010, The role of interferons in the treatment of osteosarcoma, Pediatr Blood Cancer, 54, 350, 10.1002/pbc.22136 Anderson, 2008, Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing’s sarcoma and osteosarcoma), Expert Opin Investig Drugs, 17, 1703, 10.1517/13543784.17.11.1703